Targeting Interleukin 13 for the Treatment of Atopic Dermatitis
Atopic dermatitis (AD) is a common chronic inflammatory skin condition that has a significant impact on a patient's quality of life and requires ongoing management. Conventional topical and systemic therapies do not target specific components of AD pathogenesis and, therefore, have limited effi...
Saved in:
Main Authors: | Yuliya Lytvyn (Author), Melinda Gooderham (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Interleukin-13 Inhibitors in the Treatment of Atopic Dermatitis: The Role of Tralokinumab
by: Annunziata Dattola, et al.
Published: (2024) -
Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
by: Novin Nezamololama, et al.
Published: (2020) -
Dual Interleukin-4/Interleukin-13 Blocker-induced Arthralgia Treated Successfully with Upadacitinib in a Patient with Atopic Dermatitis
by: Takayuki Tanji, et al.
Published: (2023) -
The role of interleukin-1ß and interleukin-33 in atopic dermatitis
by: Rania M. Abdel Hay, et al.
Published: (2013) -
Selective IL-13 inhibitors for the treatment of atopic dermatitis
by: Francisca Gonçalves, et al.
Published: (2021)